About this project
Newborn infants are undergoing neonatal intensive care during a period of unstable organ function and rapid central nervous growth and development. The pain they experience, but also the analgesic drugs might result in permanent negative consequences. The drugs that are routinely used are produced for and tested in the adult patient population and are used “off-label” in the neonatal population.
The purpose of this mulitcenter project is to develop evidence based analgesic and sedative treatment guidelines for sick newborn infants, taking into account the pharmacokinetic (PK), pharmacodynamic (PD), pharmacogenetic (PG) properties and the PK/PD/PG relation of these drugs used on clinical indication during neonatal intensive care. This is in accordance with the national and international directives, and serves to make it possible to provide sick infants with a safe and “tailor made” pharmacological strategy with optimal and individual dosing in the future.
- Boubou Hallberg, Karolinska Institutet
- Elisabeth Norman, Lunds universitet
- Hanna Ahl, PhD-student, Lunds universitet
- Ingmar Rosén, Skånes universitetssjukhus
- Joseph Standing, Great Ormond Street Hospital for Children, London, United Kingdom
- Marco Bartocci, Karolinska sjukhuset
- Sampsa Vanhatalo, Helsinki University Central Hospital, Finland
- Sofie Nilsson, PhD-student, Lunds universitet
- Thomas Andersson, Karolinska Institutet
- Ulf Schubert, Karolinska sjukhuset